Dianne Pulte1,2, Lina Jansen1, Felipe A Castro1, Hermann Brenner1,3,4. 1. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany. 2. Division of Hematology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania. 3. Division of Preventive Oncology, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany. 4. German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany.
Abstract
BACKGROUND: Survival for patients with hematologic malignancies has improved during the early 21st century. However, it is unclear whether older patients have benefited to the same extent as younger patients. This study examines changes in survival for older patients with the 7 most common hematologic malignancies. METHODS: Period analysis was used to examine survival for patients who were 65 years old or older and were diagnosed with a common hematologic malignancy between 1992 and 2012 with data from the Surveillance, Epidemiology, and End Results database. RESULTS: Five-year relative survival increased for older patients with hematologic malignancies with the partial exception of acute myelogenous leukemia, for which no change in survival was seen for patients who were 75 years old or older. Patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma, including the oldest patients, had especially strong improvements, with increases in 5-year relative survival for patients who were 85 years old or older of 31.5% and 39.6%, respectively, between 1997-2000 and 2009-2012. CONCLUSIONS: Despite these increases, survival rates did not reach those observed for patients aged 50 to 59 years for any hematologic malignancy. Newer therapies and a better understanding of how to treat older patients have led to increased survival expectations for older patients with most hematologic malignancies, but an age-related survival disparity persists. Cancer 2016;122:2031-40.
BACKGROUND: Survival for patients with hematologic malignancies has improved during the early 21st century. However, it is unclear whether older patients have benefited to the same extent as younger patients. This study examines changes in survival for older patients with the 7 most common hematologic malignancies. METHODS: Period analysis was used to examine survival for patients who were 65 years old or older and were diagnosed with a common hematologic malignancy between 1992 and 2012 with data from the Surveillance, Epidemiology, and End Results database. RESULTS: Five-year relative survival increased for older patients with hematologic malignancies with the partial exception of acute myelogenous leukemia, for which no change in survival was seen for patients who were 75 years old or older. Patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma, including the oldest patients, had especially strong improvements, with increases in 5-year relative survival for patients who were 85 years old or older of 31.5% and 39.6%, respectively, between 1997-2000 and 2009-2012. CONCLUSIONS: Despite these increases, survival rates did not reach those observed for patients aged 50 to 59 years for any hematologic malignancy. Newer therapies and a better understanding of how to treat older patients have led to increased survival expectations for older patients with most hematologic malignancies, but an age-related survival disparity persists. Cancer 2016;122:2031-40.
Authors: Emma Prower; Sophie Hadfield; Rohit Saha; Timothy Woo; Kar Mun Ang; Victoria Metaxa Journal: J Crit Care Date: 2022-07-15 Impact factor: 4.298
Authors: Betina Yanez; Chloe J Taub; Margaret Waltz; Alma Diaz; Diana Buitrago; Katrin Bovbjerg; Anthony Chicaiza; Rebecca Thompson; Scott Rowley; Jonathan Moreira; Kristi D Graves; Christine Rini Journal: Int J Behav Med Date: 2022-10-20
Authors: Richard J Lin; Patrick D Hilden; Theresa A Elko; Parastoo B Dahi; Armin Shahrokni; Ann A Jakubowski; Miguel-Angel Perales; Craig S Sauter; Hugo R Castro-Malaspina; Juliet N Barker; Brian C Shaffer; Roni Tamari; Esperanza B Papadopoulos; Molly A Maloy; Beatriz Korc-Grodzicki; Sergio A Giralt Journal: Blood Adv Date: 2019-01-08
Authors: Lonneke van de Poll-Franse; Simone Oerlemans; Anne Bredart; Charalampia Kyriakou; Monika Sztankay; Stephan Pallua; Laurien Daniëls; Carien L Creutzberg; Kim Cocks; Sandra Malak; Giovanni Caocci; Stefano Molica; Weichu Chie; Fabio Efficace Journal: Qual Life Res Date: 2017-11-10 Impact factor: 4.147